Troy Wilson, PhD, JD

Troy Wilson is an accomplished biotech leader with a proven track record of founding, building and leading innovative companies that deliver transformative therapies and substantial value to patients and shareholders. Dr. Wilson is a co-founder of Kura Oncology (NASDAQ: KURA), where he has served as President, Chief Executive Officer, and Chairman of the Board since the company’s inception in 2014. He also co-founded Avidity Biosciences and served as President and CEO from inception through 2019 and Chairman of its Board from inception until its acquisition by Novartis AG. Previously, Dr. Wilson co-founded and served as CEO and President of Araxes Pharma and Wellspring Biosciences, where his teams pioneered discovery and development of small-molecule inhibitors targeting the KRAS oncoprotein — one of oncology’s most challenging targets. Earlier in his career, Dr. Wilson co-founded and served as President and CEO of Intellikine from inception through to acquisition by Takeda Pharmaceutical Company Limited in 2011. He also co-founded Ambrx, where he served as Chief Business Officer, prior to its acquisition by Johnson & Johnson Innovative Medicines in 2024. In addition to his leadership roles, Dr. Wilson currently serves on the boards of Atrium Therapeutics, Puma Biotechnology, Cartography Biosciences, Montara Therapeutics and Cipher Genetics. He holds a J.D. from New York University and earned his Ph.D. in bioorganic chemistry and B.A. in biophysics from the University of California, Berkeley.